

Local Inhibition of MEK/Akt Prevents Cellular Growth in Human Congenital Melanocytic Nevi

Thomas Rouillé¹, Selim Aractingi^{1,2}, Natacha Kadlub³, Sylvie Fraitag⁴, Alexandre How-Kit⁵, Philippe Moguelet⁶, Arnaud Picard³, Romain H. Fontaine¹, Sarah Guégan^{1,2}

¹INSERM UMRS 938, Sorbonne Université, Paris; ²Dermatology, Hôpital Cochin, AP-HP, Paris; ³Plastic Surgery and ⁴Pathology, Hôpital Necker-Enfants-Malades, AP-HP, Paris; ⁵Laboratory for Functional Genomics, Fondation Jean Dausset – CEPH, Paris; ⁶Pathology, Hôpital Tenon, AP-HP, Paris, France.


INTRODUCTION

Large congenital melanocytic nevi (ICMN) are benign melanocytic tumors associated with an increased risk of melanoma transformation. They harbour predominantly a post-zygotic **somatic NRAS mutation**^{1,2}. Management is based exclusively on iterative surgical procedures in the absence of validated medical therapy. The aim of our study was to analyze in preclinical models of ICMN the impact of an intra-lesional medical treatment targeting signaling pathways downstream of NRAS.


METHODS

Seventeen patients harboring NRAS-mutated ICMN were included. MEK and AKT inhibitors were tested alone or in combination in different *in vitro*, *ex vivo* and *in vivo* assays using patient-derived nevocytes or CMN tissue.


In vitro
Patient-derived ICMN nevocytes



Ex vivo
ICMN tissue explants cultured for 5 days




In vivo
Full thickness ICMN xenografts in Rag2^{-/-} immunocompromised mice



RESULTS

Nevocytes obtained from ICMN displayed an overactivation of MAPK and AKT pathways when compared to primary melanocytes NHEM. MEK (Binimetinib) and AKT (GSK690693) inhibitors reduced nevosphere diameter in sphere-forming assays, as well as nevocyte cell viability and proliferation in *in vitro* assays (A). Standardized ICMN explants were then cultured *ex vivo* with the same inhibitors which induced a decrease in MelanA⁺ and Sox10⁺ cells in both epidermis and dermis (B). A similar reduction in melanocyte cell numbers was not observed in control normal skin explants. Finally, intradermal injections of these inhibitors were performed within standardized ICMN xenografts in Rag2^{-/-} mice. They induced a dramatic decrease in nevocytes in treated xenografts which persisted 30 days after the end of treatment (C). Melanocytes in control normal skin xenografts were not affected by a similar treatment.



CONCLUSION

Using nevus explant and xenograft preclinical models, we demonstrated that intradermal MEK/AKT inhibition might serve as neo-adjuvant therapy for the treatment of NRAS-mutated CMN to avoid iterative surgeries. Additional preclinical and clinical studies are of course needed.